Somatuline
ApprovedSmall molecule
Somatuline is one of 4 small molecule programs targeting Dumping Syndrome. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Dumping Syndrome
#DrugCompanyPhaseTrials
1Lanreotide Acetate
AAlbireo, an Ipsen Company
Approved
Signifor
RRECORDATI GROUP
Phase 2
SOM230
NovartisPhase 2
Somatuline
RRadboud University Medical Center
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Somatuline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details